FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

EcoR1 Capital, LLC		 2. Issuer Name and Ticker or Trading Symbol

Odonate Therapeutics, Inc. [ ODT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

357 TEHAMA STREET #3		 3. Date of Earliest Transaction (MM/DD/YYYY)

12/1/2021
(Street)

SAN FRANCISCO, CA 94103
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/1/2021  P  185941 (2)A$1.66 5701669 I See Note 1 (1)
Common Stock 12/1/2021  S  185941 (2)D$1.66 5701669 I See Note 1 (1)
Common Stock 12/9/2021  S  156669 (3)D$1.819 5545000 I See Note 1 (1)
Common Stock 12/10/2021  S  5000000 (4)D$1.66 545000 I See Note 1 (1)
Common Stock 12/10/2021  S  545000 (5)D$1.5549 0 I See Note 1 (1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
(2) These securities were transferred from another Fund managed by EcoR1 to Qualified Fund as part of a periodic rebalancing of the portfolios of the Funds. After this transaction, Qualified Fund held 5,185,698 shares of the Issuer's Common Stock, and the other fund held 515,971 shares.
(3) Qualified Fund sold 142,491 of these shares. After this transaction, Qualified Fund held 5,043,207 shares of the Issuer's Common Stock.
(4) Qualified Fund sold 4,547,500 of these shares. After this transaction, Qualified Fund held 495,707 shares of the Issuer's Common Stock.
(5) Qualified Fund sold 495,707 of these shares. After this transaction, Qualified Fund held no shares of the Issuer's Common Stock.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
EcoR1 Capital, LLC
357 TEHAMA STREET #3
SAN FRANCISCO, CA 94103
X
Signatures
Oleg Nodelman, Manager of EcoR1 Capital, LLC12/10/2021
**Signature of Reporting PersonDate
Odonate Therapeutics (NASDAQ:ODT)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Odonate Therapeutics.
Odonate Therapeutics (NASDAQ:ODT)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Odonate Therapeutics.